Muscle wasting and severe weight loss affect four out of five pancreatic cancer patients, directly causing nearly one-third of deaths from this aggressive disease. This metabolic devastation, known as cachexia, represents far more than simple appetite loss—it's a systemic breakdown that renders patients too weak for life-extending treatments.
The mechanism centers on specific inflammatory proteins released through tumor-host interactions. Growth differentiation factor 15 (GDF-15) and parathyroid hormone-related protein (PTHrP) emerge as key drivers, triggering appetite suppression and accelerating muscle breakdown. These mediators create a cascade affecting multiple organ systems simultaneously, depleting both skeletal muscle and adipose tissue while promoting chronic inflammation. Current diagnostic criteria focus on unintentional weight loss exceeding 5% of body mass within six months, combined with BMI measurements below specific thresholds.
This comprehensive review synthesizes emerging therapeutic approaches that target the underlying inflammatory pathways rather than simply addressing symptoms. The findings illuminate why traditional nutritional support often fails in pancreatic cancer—the problem operates at the cellular and hormonal level, requiring intervention strategies that address systemic inflammation and metabolic dysregulation. Understanding these specific protein mediators opens possibilities for targeted interventions that could preserve muscle mass and improve treatment tolerance. However, the complexity of this multi-organ syndrome suggests that effective treatments will likely require combination approaches addressing inflammation, metabolism, and nutritional support simultaneously. The research underscores how cachexia transforms from a side effect into a primary therapeutic target for improving both quality of life and survival outcomes in pancreatic cancer.